Inari Medical Faces Lawsuit Over Alleged Illegal Business Practices

Author:

Inari Medical, Inc. (NASDAQ: NARI) stockholders who have suffered significant losses are being urged to take action by Rosen Law Firm, a prominent global investor rights law firm. The firm reminds purchasers of common stock of Inari Medical between February 24, 2022, and February 28, 2024, about the upcoming July 12, 2024, lead plaintiff deadline.

Investors who bought Inari Medical common stock during the specified period may be entitled to compensation without having to pay any out-of-pocket fees or costs through a contingency fee arrangement. To join the class action lawsuit, individuals can visit Rosen Law Firm’s submission form at https://rosenlegal.com/submit-form/?case_id=22855, call toll-free at 866-767-3653, or email [email protected] for more information.

The lawsuit alleges that Inari Medical’s positive discussions about its growth prospects were misleading, as the company was engaged in illegal business practices. Specifically, it is claimed that Inari Medical violated the federal Anti-Kickback Statute and Civil False Claims Act by unlawfully compensating healthcare professionals. The lawsuit further accuses the company of misleading investors about its business expenses to conceal these illicit activities. As a result, investors are believed to have suffered damages.

Rosen Law Firm is recognized for its expertise in securities class actions and shareholder derivative litigation. The firm has secured substantial settlements in these types of cases and has a history of success. Investors are encouraged to consider experienced counsel when choosing representation in such matters.

While the class action lawsuit has been filed, no class has been certified yet. Investors who wish to be represented by counsel can choose their legal representative, or they can remain as absent class members. Serving as a lead plaintiff is not a requirement to share in any potential future recovery.

For updates and further information, interested parties can follow Rosen Law Firm on LinkedIn, Twitter, and Facebook. The firm’s contact details are Laurence Rosen, Esq., Phillip Kim, Esq., The Rosen Law Firm, P.A., 275 Madison Avenue, 40th Floor, New York, NY 10016. They can be reached by telephone at (212) 686-1060, toll-free at (866) 767-3653, or via email at [email protected]. Additional information is available on the firm’s website at www.rosenlegal.com. This is attorney advertising, and past results do not guarantee future outcomes.

Inari Medical, a medical device company listed on the NASDAQ (NASDAQ: NARI), is currently facing a lawsuit over alleged illegal business practices. The lawsuit, filed by Rosen Law Firm, claims that Inari Medical engaged in illegal activities that violated the federal Anti-Kickback Statute and Civil False Claims Act.

The lawsuit alleges that the company misled investors about its growth prospects by engaging in unlawful compensation of healthcare professionals. This violates the federal Anti-Kickback Statute, which prohibits the exchange of remuneration to induce or reward referrals of items or services reimbursable by federal healthcare programs. Inari Medical is also accused of misleading investors about its business expenses to hide these illicit activities.

Investors who purchased Inari Medical common stock between February 24, 2022, and February 28, 2024, may be eligible for compensation through the class action lawsuit. Rosen Law Firm is offering representation to investors who wish to join the lawsuit and seek potential recovery. Interested parties can visit Rosen Law Firm’s submission form at [link](https://rosenlegal.com/submit-form/?case_id=22855), call toll-free at 866-767-3653, or email [email protected] for more information.

It is important to note that the class action lawsuit has been filed, but no class has been certified at this time. Investors who choose representation can select their legal representative or remain as absent class members. Leading the class action is not mandatory to participate in any potential future recovery.

As for the market trends and forecasts related to Inari Medical, it is important to conduct independent research and analysis. Market trends can be affected by various factors, including legal challenges, regulatory issues, and competitive landscape. It is advisable to consult reliable financial and market sources for up-to-date information on the company.

While the current lawsuit presents a challenge for Inari Medical, it is crucial to consider both advantages and disadvantages when evaluating the situation. Potential advantages for investors participating in the class action lawsuit include the possibility of compensation for damages suffered due to the alleged illegal business practices. Engaging legal representation with experience in securities class actions, such as Rosen Law Firm, can enhance the chances of a favorable outcome.

On the other hand, disadvantages may include uncertainties regarding the outcome of the lawsuit and potential delays in the legal process. It is also important to remember that past results do not guarantee future outcomes, and each case is unique.

For more information and updates on the lawsuit, interested parties can follow Rosen Law Firm on [LinkedIn](https://www.linkedin.com/company/rosenlawfirm/), [Twitter](https://twitter.com/rosen_firm), and [Facebook](https://www.facebook.com/rosenlawfirm/). Contact details for Rosen Law Firm are Laurence Rosen, Esq., Phillip Kim, Esq., The Rosen Law Firm, P.A., 275 Madison Avenue, 40th Floor, New York, NY 10016. They can be reached by telephone at (212) 686-1060, toll-free at (866) 767-3653, or via email at [email protected]. Additional information is available on the firm’s website at [www.rosenlegal.com](https://www.rosenlegal.com/).

Note: The provided URLs are for the main domain of each platform to ensure validity.